United States Cancer Pain Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global cancer pain market was valued at US$ 7.45 Billion in 2023. The market size reached US$ 7.82 Billion in 2024 and is expected to reach US$ 12.45 Billion by 2033, growing at a CAGR of 5.9% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cancer-pain-market?sb

Key Development:

United States: Recent Cancer Pain Developments

✅ In December 2025, researchers proposed a hybrid AI system that predicts cancer pain episodes up to 72 hours in advance for hospitalized lung cancer patients by combining machine learning with large language models, paving the way for earlier, more precise pain intervention.

✅ In November 2025, extensive clinical review analyses emphasised the urgent need for multimodal, precision‐based cancer pain strategies moving beyond traditional opioid‐centric approaches to include targeted therapies and supportive care for individualized pain relief.

✅ In October 2025, a U.S. study led by Johns Hopkins found that bupivacaine and rimegepant drugs already approved for other pain types may both relieve pain and slow bone cancer growth in preclinical models by inhibiting nerve‐tumor signaling, hinting at dual‐benefit therapy for cancer pain sufferers.

✅ In late 2025, clinicians highlighted multiple award‐recognised research abstracts at the Annual Pain Medicine Meeting showing innovative techniques and approaches to cancer and chronic pain care, with emphasis on improved safety and management strategies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-pain-market

Japan: Recent Cancer Pain Developments

✅ In December 2025, Japan's 15th Pain Clinic public lecture "Living Well with Cancer Pain" was announced for January 2026, focusing on educating patients and caregivers on managing cancer‐related pain and improving quality of life through multidisciplinary strategies.

✅ In November 2025, the VENTI 2025 international conference on vascular and pain intervention was held in Tokyo, gathering pain treatment specialists worldwide to share advances in catheter‐based and interventional pain therapies that may benefit cancer pain management.

✅ In October 2025, a multicenter questionnaire study reported that over 30 % of Japanese cancer patients experience significant pain including neuropathic pain and many feel their pain assessment could be improved, highlighting the need for earlier, more proactive cancer pain screening and management practices.

✅ In November 2025, a Japanese clinical news report raised concerns about the limited effectiveness and safety of the weak opioid tram@dol for cancer and chronic pain, prompting renewed discussion on optimizing analgesic choices in Japan's oncology pain care.

Europe: Recent Cancer Pain Developments

✅ In December 2025, European clinical discussions increasingly focused on novel pain‐forecasting tools across oncology care that could help pain management teams anticipate pain escalation in cancer patients for more proactive analgesic adjustments.

✅ In December 2025, meta‐analyses and clinical expert panels highlighted the importance of individualized pain assessment pathways in European oncology centers - aiming to implement tailored regimens that reduce reliance on opioids and address complex pain profiles in advanced cancer.

✅ In November 2025, ongoing Phase 2 global clinical trials on epidural resiniferatoxin (RTX) a plant‐derived non‐opioid molecule continued enrolling subjects in Europe and North America to assess its effectiveness against intractable cancer pain not relieved by standard treatments.

✅ In late 2025, researchers across Europe have been sharing insights at oncology and pain conferences on integrating predictive analytics and patient‐reported data to optimize cancer pain control and anticipate breakthrough pain episodes.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-pain-market?sb

Key Players:

=> CK Life Sciences (WEX Pharmaceuticals Inc.), Mundipharma International, Orexo AB, DAIICHI SANKYO COMPANY, LIMITED., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., Grünenthal, Teva Pharmaceutical Industries Ltd., Galena Biopharma, Meda Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and Dogwood Therapeutics, Inc., among others.

Key Segments:

By Drug Class

Opioids - ~35% share

Widely prescribed for moderate to severe cancer pain management; major segment in hospital and homecare settings.

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) - ~20% share

Commonly used for mild to moderate pain relief; preferred in combination therapies and outpatient care.

Morphine - ~15% share

A standard treatment for severe cancer-related pain; high adoption in hospitals and specialty clinics.

Non-Opioids - ~15% share

Includes acetaminophen and other analgesics; used for mild pain management and as complementary therapy.

Nerve Blockers - ~10% share

Increasing adoption in procedural and post-operative pain management for cancer patients.

Others - ~5% share

Experimental or less common pain management drugs, including adjuvants and novel therapies.

By Application

Lung Cancer - ~20% share

High prevalence and associated pain drives strong demand for opioids, NSAIDs, and nerve blockers.

Colorectal Cancer - ~15% share

Pain management focused on parenteral and oral routes; hospital settings dominate usage.

Breast Cancer - ~20% share

Combination therapies for pain relief; strong adoption in homecare and specialty clinics.

Prostate Cancer - ~15% share

Treatment protocols include opioids and non-opioids; increasing homecare usage.

Blood Cancer - ~10% share

Hospital-based administration prevalent; targeted therapies complement analgesics.

Others - ~20% share

Includes other cancer types like pancreatic, ovarian, and head & neck; mix of drug classes applied.

By Route of Administration

Oral - ~40% share

Convenient for homecare and outpatient treatment; growing adoption in specialty clinics.

Parenteral - ~50% share

Hospitals remain the primary end-user; essential for rapid pain control and severe cases.

Others - ~10% share

Includes transdermal patches, subcutaneous injections, and experimental delivery routes.

By End-User

Hospitals - ~50% share

Largest end-user; inpatient and procedural pain management drive demand for opioids, morphine, and parenteral routes.

Homecare - ~20% share

Rising due to outpatient pain management and hospice care; oral medications dominate.

Specialty Clinics - ~20% share

Focus on cancer treatment centers offering targeted pain management therapies.

Others - ~10% share

Includes research institutions, palliative care facilities, and rehabilitation centers.

By Region

North America - ~35% Share

Strong healthcare infrastructure and high adoption of advanced pain management therapies; opioids dominate.

Europe - ~25% Share

Growing demand for homecare pain management and specialty clinic services; regulatory focus on opioid use.

Asia-Pacific - ~20% Share

Expanding oncology treatment facilities and rising awareness; increasing use of NSAIDs and non-opioids.

South America - ~10% Share

Moderate adoption due to developing healthcare infrastructure; hospitals are primary end-users.

Middle East & Africa - ~10% Share

Emerging market for cancer pain management; growth opportunities in hospital and homecare segments.

FAQ

What is the current size of the Cancer pain Market?

A: In 2024, the Cancer pain Market was valued at US$ 7.82 Billion, reflecting its strong industry presence.

Q2: How large is the Cancer pain Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Cancer pain Market will grow to around US$ 12.45 Billion, demonstrating significant expansion.

Q3: What is the growth rate of the Cancer pain Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.9% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.